{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:05:15Z","timestamp":1777363515365,"version":"3.51.4"},"reference-count":131,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Moving from indication to transplantation is a critical process in myelofibrosis. Most of guidelines specifically focus on either myelofibrosis disease or transplant procedure, and, currently, no distinct indication for the management of MF candidates to transplant is available. Nevertheless, this period of time is crucial for the transplant outcome because engraftment, non-relapse mortality, and relapse incidence are greatly dependent upon the pre-transplant management. Based on these premises, in this review, we will go through the path of identification of the MF patients suitable for a transplant, by using disease-specific prognostic scores, and the evaluation of eligibility for a transplant, based on performance, comorbidity, and other combined tools. Then, we will focus on the process of donor and conditioning regimens\u2019 choice. The pre-transplant management of splenomegaly and constitutional symptoms, cytopenias, iron overload and transplant timing will be comprehensively discussed. The principal aim of this review is, therefore, to give a practical guidance for managing MF patients who are potential candidates for allo-HCT.<\/jats:p>","DOI":"10.3390\/cells11030553","type":"journal-article","created":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T20:36:47Z","timestamp":1644179807000},"page":"553","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-9697","authenticated-orcid":false,"given":"Nicola","family":"Polverelli","sequence":"first","affiliation":[{"name":"Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-9028","authenticated-orcid":false,"given":"Mirko","family":"Farina","sequence":"additional","affiliation":[{"name":"Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariella","family":"D\u2019Adda","sequence":"additional","affiliation":[{"name":"Hematology Division, Department of Oncology, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Damiani","sequence":"additional","affiliation":[{"name":"2nd Division of General Surgery, Department of Medical & Surgical Sciences, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Grazioli","sequence":"additional","affiliation":[{"name":"Department of Radiology, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Leoni","sequence":"additional","affiliation":[{"name":"Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0907-130X","authenticated-orcid":false,"given":"Michele","family":"Malagola","sequence":"additional","affiliation":[{"name":"Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-2624","authenticated-orcid":false,"given":"Simona","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy"},{"name":"CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[{"name":"Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5045\/br.2018.53.1.3","article-title":"The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era","volume":"53","author":"Morello","year":"2018","journal-title":"Blood Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"96.e1","DOI":"10.1016\/j.jtct.2021.11.006","article-title":"Gitmo registry study on allogeneic transplantation in patients aged over 60 from 2000 to 2017. Improvements and criticisms","volume":"28","author":"Malagola","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/hon.2429","article-title":"Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study","volume":"36","author":"Palandri","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00277-014-2183-0","article-title":"Ruxolitinib-associated tuberculosis: A case of successful ruxolitinib rechallenge","volume":"94","author":"Palandri","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bjh.13758","article-title":"Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly","volume":"174","author":"Palandri","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"79073","DOI":"10.18632\/oncotarget.18674","article-title":"Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis","volume":"8","author":"Palandri","year":"2017","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.leukres.2018.10.001","article-title":"Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients","volume":"74","author":"Palandri","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41409-021-01305-x","article-title":"Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: A CMWP of EBMT retrospective analysis","volume":"56","author":"McLornan","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: A consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kroger","year":"2015","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kroger","year":"2015","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.3324\/haematol.2013.101733","article-title":"The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis","volume":"99","author":"Pereira","year":"2014","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.seminhematol.2018.05.013","article-title":"Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and\/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study","volume":"55","author":"Palandri","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/j.bbmt.2019.03.024","article-title":"Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET prognostic model for prediction of outcome in polycythemia vera and essential thrombocythemia myelofibrosis after allogeneic stem cell transplantation","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: Phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3324\/haematol.2018.206151","article-title":"State-of-the-art review: Allogeneic stem cell transplantation for myelofibrosis in 2019","volume":"104","author":"McLornan","year":"2019","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","article-title":"Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis","volume":"25","author":"Tamari","year":"2019","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: Mutation and karyotype-enhanced International Prognostic Scoring System for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41409-019-0683-1","article-title":"The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: A case-based review","volume":"55","author":"Tiribelli","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bbmt.2006.05.015","article-title":"Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation","volume":"12","author":"Artz","year":"2006","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood-2012-03-414573","article-title":"Validation of the hematopoietic cell transplantation-specific comorbidity index: A prospective, multicenter GITMO study","volume":"120","author":"Raimondi","year":"2012","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bbmt.2015.04.004","article-title":"Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: A center for international blood and marrow transplant research study","volume":"21","author":"Sorror","year":"2015","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/ajh.26279","article-title":"Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry","volume":"96","author":"Pereira","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cger.2011.10.001","article-title":"Comprehensive geriatric assessment and its clinical impact in oncology","volume":"28","author":"Liu","year":"2012","journal-title":"Clin. Geriatr. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/bmt.2017.192","article-title":"Frailty: The missing piece of the pre- hematopoietic cell transplantation assessment?","volume":"53","author":"Hegde","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41409-020-0934-1","article-title":"Multidimensional geriatric assessment for elderly hematological patients (\u226560 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients","volume":"55","author":"Polverelli","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: A prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kroger","year":"2009","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: A cohort analysis from the center for international blood and marrow transplant research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","article-title":"MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis","volume":"124","author":"Rondelli","year":"2014","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.bbmt.2015.09.028","article-title":"Improved outcome of alternative donor transplantations in patients with myelofibrosis: From unrelated to haploidentical family donors","volume":"22","author":"Bregante","year":"2016","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bbmt.2018.10.017","article-title":"Family mismatched allogeneic stem cell transplantation for myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and MARROW transplantation","volume":"25","author":"Raj","year":"2019","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.bbmt.2019.02.019","article-title":"Comparison of outcomes of allogeneic transplantation for primary myelofibrosis among hematopoietic stem cell source groups","volume":"25","author":"Murata","year":"2019","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.bbmt.2014.06.011","article-title":"Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis","volume":"20","author":"Robin","year":"2014","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","article-title":"Allogeneic haematopoietic stem cell transplantation for myelofibrosis: A report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"152","author":"Robin","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1038\/s41409-021-01438-z","article-title":"Myelofibrosis: Let\u2019s go high!","volume":"56","author":"Ballen","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Czerw, T., Iacobelli, S., Malpassuti, V., Koster, L., Kroger, N., Robin, M., Maertens, J., Chevallier, P., Watz, E., and Poire, X. (2021). Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: A study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant.","DOI":"10.1038\/s41409-021-01540-2"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2017.199","article-title":"Donor and recipient age, gender and ABO incompatibility regardless of donor source: Validated criteria for donor selection for haematopoietic transplants","volume":"32","author":"Wang","year":"2018","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","article-title":"Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia","volume":"13","author":"Kerbauy","year":"2007","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_54","first-page":"2831","article-title":"Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bbmt.2016.02.019","article-title":"Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis","volume":"22","author":"Robin","year":"2016","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbmt.2018.12.064","article-title":"Busulfan- or thiotepa-based conditioning in myelofibrosis: A phase II multicenter randomized study from the GITMO Group","volume":"25","author":"Patriarca","year":"2019","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: A retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ajh.26042","article-title":"Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen","volume":"96","author":"Chiusolo","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41409-021-01222-z","article-title":"Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: An outcome analysis from the Chronic Malignancies Working Party of the EBMT","volume":"56","author":"Battipaglia","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/10428194.2020.1827246","article-title":"Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: A single center experience","volume":"62","author":"Memoli","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41409-019-0653-7","article-title":"Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis","volume":"55","author":"Shouval","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","article-title":"Allogeneic haematopoietic cell transplantation for myelofibrosis: Proposed definitions and management strategies for graft failure, poor graft function and relapse: Best practice recommendations of the EBMT Chronic Malignancies Working Party","volume":"35","author":"McLornan","year":"2021","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2141.1990.tb02609.x","article-title":"Myelofibrosis with myeloid metaplasia: Clinical and haematological parameters predicting survival in a series of 133 patients","volume":"75","author":"Visani","year":"1990","journal-title":"Br. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.3324\/haematol.2018.193763","article-title":"Genomic characterization of spleens in patients with myelofibrosis","volume":"103","author":"Zimran","year":"2018","journal-title":"Haematologica"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1182\/blood.V97.11.3665","article-title":"Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia","volume":"97","author":"Mesa","year":"2001","journal-title":"Blood"},{"key":"ref_67","first-page":"815","article-title":"Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: Heterogeneous morphology and cytological composition","volume":"25","author":"Prakash","year":"2012","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood.V97.7.2180","article-title":"Splenectomy and hemopoietic stem cell transplantation for myelofibrosis","volume":"97","author":"Li","year":"2001","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.26020","article-title":"Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: A predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/hon.2509","article-title":"Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients","volume":"36","author":"Polverelli","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.17192","article-title":"Second primary malignancy in myelofibrosis patients treated with ruxolitinib","volume":"193","author":"Polverelli","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2141.2011.09009.x","article-title":"Risk models predicting survival after reduced-intensity transplantation for myelofibrosis","volume":"157","author":"Alchalby","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/bmt.2016.98","article-title":"Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis","volume":"51","author":"Alchalby","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: A study of the CMWP of EBMT","volume":"35","author":"Kroger","year":"2021","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/bmt.2013.173","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib","volume":"49","author":"Jaekel","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/leu.2014.86","article-title":"JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET\/PV myelofibrosis","volume":"28","author":"Stubig","year":"2014","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood.V122.21.306.306","article-title":"Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: A preliminary descriptive report of the JAK ALLO Study, a phase II trial sponsored by Goelams-FIM in collaboration with the Sfgmtc","volume":"122","author":"Robin","year":"2013","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1097\/TXD.0000000000000607","article-title":"Evaluation of short-term Ruxolitinib tapering strategy before allogeneic stem cell transplantation for primary myelofibrosis through the transition of serum cytokines and growth factors","volume":"2","author":"Shiratori","year":"2016","journal-title":"Transpl. Direct"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41409-019-0523-3","article-title":"Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis","volume":"55","author":"Salit","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000506758","article-title":"A prospective pilot study of graft-versus-host disease prophylaxis with post-transplantation Cyclophosphamide and Ruxolitinib in patients with myelofibrosis","volume":"144","author":"Morozova","year":"2021","journal-title":"Acta Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","article-title":"Peritransplantation Ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation","volume":"24","author":"Kroger","year":"2018","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/ejh.13099","article-title":"Impact of Ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"101","author":"Christopeit","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbmt.2018.09.001","article-title":"Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ali, H., Tsai, N.C., Synold, T., Mokhtari, S., Tsai, W., Palmer, J., Stiller, T., Salhotra, A., Rahmanuddin, S., and Pullarkat, V.A. (2021). Peritransplant Ruxolitinib administration is safe and effective in patients with myelofibrosis: A pilot open-label study. Blood Adv.","DOI":"10.1182\/bloodadvances.2021005035"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/s41409-021-01252-7","article-title":"Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups","volume":"56","author":"Robin","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of Fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for Ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with Ruxolitinib (SIMPLIFY 2): A randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including Ruxolitinib, in patients with myelofibrosis: A randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.hoc.2020.12.003","article-title":"Current clinical investigations in myelofibrosis","volume":"35","author":"Venugopal","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbmt.2017.03.002","article-title":"The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Robin","year":"2017","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"key":"ref_99","first-page":"328","article-title":"Preventing infections in children and adults with asplenia","volume":"Volume 2020","author":"Lee","year":"2020","journal-title":"Hematology 2014, the American Society of Hematology Education Program Book"},{"key":"ref_100","first-page":"3630","article-title":"Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia","volume":"91","author":"Barosi","year":"1998","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajh.26034","article-title":"Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study","volume":"96","author":"Bossard","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1054\/blre.1999.0110","article-title":"Splenic irradiation in myelofibrosis with myeloid metaplasia: A review","volume":"13","author":"Elliott","year":"1999","journal-title":"Blood Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1182\/blood.V124.21.3170.3170","article-title":"Splenic irradiation and a reduced-intensity conditioning regimen prior to allogeneic stem-cell transplantation for myelofibrosis","volume":"124","author":"Vyas","year":"2014","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.23505","article-title":"Risk factors for leukemic transformation in patients with primary myelofibrosis","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00277-015-2397-9","article-title":"Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: The combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly\/constitutional symptoms","volume":"94","author":"Polverelli","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/nyas.13027","article-title":"Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major","volume":"1368","author":"Angelucci","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jtct.2020.11.007","article-title":"Iron toxicity and chelation therapy in hematopoietic stem cell transplant","volume":"27","author":"Isidori","year":"2021","journal-title":"Transpl. Cell Ther."},{"key":"ref_108","first-page":"1","article-title":"Current review of iron overload and related complications in hematopoietic stem cell transplantation","volume":"34","author":"Atilla","year":"2017","journal-title":"Turk. J. Haematol. Off. J. Turk. Soc. Haematol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhai, W., Zhao, M., Li, D., Chai, X., Cao, X., Meng, J., Chen, J., Xiao, X., and Li, Q. (2015). Effects of iron overload on the bone marrow microenvironment in mice. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120219"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"10181","DOI":"10.1038\/srep10181","article-title":"ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem\/progenitor cells in mice","volume":"5","author":"Chai","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ejh.12309","article-title":"The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice","volume":"93","author":"Okabe","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/10428194.2015.1046866","article-title":"Long-term results of prednisone treatment for the anemia of myelofibrosis","volume":"57","author":"Xicoy","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1532\/IJH97.06135","article-title":"The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: Retrospective analysis of 39 patients in Japan","volume":"85","author":"Shimoda","year":"2007","journal-title":"Int. J. Hematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2141.2005.05524.x","article-title":"Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: Long-term results in 30 patients","volume":"129","author":"Cervantes","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/sj.leu.2404398","article-title":"Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome","volume":"20","author":"Mesa","year":"2006","journal-title":"Leukemia"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3324\/haematol.12416","article-title":"Low-dose thalidomide in myelofibrosis","volume":"93","author":"Weinkove","year":"2008","journal-title":"Haematologica"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","article-title":"Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial","volume":"22","author":"Marchetti","year":"2004","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","article-title":"Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: Results in 20 patients and review of the literature","volume":"127","author":"Cervantes","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01266.x","article-title":"Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level","volume":"83","author":"Huang","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.12846","article-title":"Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis","volume":"98","author":"Correa","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.15450","article-title":"The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib","volume":"182","author":"Crisa","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"752192","DOI":"10.3389\/fonc.2021.752192","article-title":"From biology to clinical practice: Iron chelation therapy with deferasirox","volume":"11","author":"Palumbo","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ejh.12674","article-title":"Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase","volume":"96","author":"Latagliata","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1111\/bjh.15964","article-title":"Deferasirox in the management of iron-overload in patients with myelofibrosis: A multicentre study from the Rete Ematologica Lombarda (IRON-M study)","volume":"186","author":"Elli","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Tanaka, H., Espinoza, J.L., Fujiwara, R., Rai, S., Morita, Y., Ashida, T., Kanakura, Y., and Matsumura, I. (2019). Excessive reactive iron impairs hematopoiesis by affecting both immature hematopoietic cells and stromal cells. Cells, 8.","DOI":"10.3390\/cells8030226"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Gagelmann, N., Wolschke, C., Salit, R.B., Schroeder, T., Ditschkowski, M., Panagiota, V., Cassinat, B., Thol, F., Badbaran, A., and Robin, M. (2022). Reduced intensity hematopoietic stem cell transplantation for myelofibrosis in accelerated-phase. Blood Adv.","DOI":"10.1182\/bloodadvances.2021006827"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1182\/bloodadvances.2020002621","article-title":"Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/3\/553\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:14:24Z","timestamp":1760134464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/3\/553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,5]]},"references-count":131,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cells11030553"],"URL":"https:\/\/doi.org\/10.3390\/cells11030553","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,5]]}}}